244 related articles for article (PubMed ID: 34347204)
1. How to Use Statins in Secondary Prevention of Atherosclerotic Diseases: from the Beneficial Early Initiation to the Potentially Unfavorable Discontinuation.
Kadoglou NPE; Stasinopoulou M
Cardiovasc Drugs Ther; 2023 Apr; 37(2):353-362. PubMed ID: 34347204
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Trends in Statin Therapy for Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults From 2007 to 2016.
Yao X; Shah ND; Gersh BJ; Lopez-Jimenez F; Noseworthy PA
JAMA Netw Open; 2020 Nov; 3(11):e2025505. PubMed ID: 33216139
[TBL] [Abstract][Full Text] [Related]
3. Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease.
Paraskevas KI; Gloviczki P; Antignani PL; Comerota AJ; Dardik A; Davies AH; Eckstein HH; Faggioli G; Fernandes E Fernandes J; Fraedrich G; Geroulakos G; Golledge J; Gupta A; Gurevich VS; Jawien A; Jezovnik MK; Kakkos SK; Knoflach M; Lanza G; Liapis CD; Loftus IM; Mansilha A; Nicolaides AN; Pini R; Poredos P; Proczka RM; Ricco JB; Rundek T; Saba L; Schlachetzki F; Silvestrini M; Spinelli F; Stilo F; Suri JS; Svetlikov AV; Zeebregts CJ; Chaturvedi S; Veith FJ; Mikhailidis DP
Prog Cardiovasc Dis; 2022; 73():41-47. PubMed ID: 35605696
[TBL] [Abstract][Full Text] [Related]
4. Statin Discontinuation and Cardiovascular Events Among Older People in Denmark.
Thompson W; Morin L; Jarbøl DE; Andersen JH; Ernst MT; Nielsen JB; Haastrup P; Schmidt M; Pottegård A
JAMA Netw Open; 2021 Dec; 4(12):e2136802. PubMed ID: 34854906
[TBL] [Abstract][Full Text] [Related]
5. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.
Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK
BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597
[TBL] [Abstract][Full Text] [Related]
6. HMG CoA reductase inhibitors (statins) for kidney transplant recipients.
Palmer SC; Navaneethan SD; Craig JC; Perkovic V; Johnson DW; Nigwekar SU; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD005019. PubMed ID: 24470059
[TBL] [Abstract][Full Text] [Related]
7. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
[TBL] [Abstract][Full Text] [Related]
8. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
9. Lipid-lowering drugs in ischemic stroke prevention and their influence on acute stroke outcome.
Fuentes B; Martínez-Sánchez P; Díez-Tejedor E
Cerebrovasc Dis; 2009; 27 Suppl 1():126-33. PubMed ID: 19342842
[TBL] [Abstract][Full Text] [Related]
10. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
11. Are Statins Indicated in Senior Citizens? A Review of Statin Therapy in the Elderly.
Wylie LE; Waterbrook AL; Dalen JE
Am J Med; 2022 Apr; 135(4):426-429. PubMed ID: 34856186
[TBL] [Abstract][Full Text] [Related]
12. A systematic review and economic evaluation of statins for the prevention of coronary events.
Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
[TBL] [Abstract][Full Text] [Related]
13. Impact of changing reimbursement criteria on statin treatment patterns among patients with atherosclerotic cardiovascular disease or cardiovascular risk factors.
Hsu CY; Chen WJ; Chen HM; Tsai HY; Hsiao FY
J Clin Pharm Ther; 2021 Apr; 46(2):415-423. PubMed ID: 33180353
[TBL] [Abstract][Full Text] [Related]
14. Current status of lipid management in acute coronary syndrome.
Fujisue K; Tsujita K
J Cardiol; 2017 Aug; 70(2):101-106. PubMed ID: 28325524
[TBL] [Abstract][Full Text] [Related]
15. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
[TBL] [Abstract][Full Text] [Related]
16. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
Bruckert E; Ferrières J
Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
[TBL] [Abstract][Full Text] [Related]
17. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
18. [Management of hypercholesterolemia in patients with acute coronary syndrome: current mechanisms and future perspectives].
Lettino M
G Ital Cardiol (Rome); 2016 Apr; 17(4 Suppl 1):31S-7. PubMed ID: 27312021
[TBL] [Abstract][Full Text] [Related]
19. The evolving role of statins in the management of atherosclerosis.
Vaughan CJ; Gotto AM; Basson CT
J Am Coll Cardiol; 2000 Jan; 35(1):1-10. PubMed ID: 10636252
[TBL] [Abstract][Full Text] [Related]
20. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
